How do pediatric transition-to-adult-care clinic nurses explain to Spanish-speaking families why their child is being transferred to adult care when they are doing well?

The transfer-when-things-are-finally-good conversation is among the most emotionally difficult in the transition clinic because the family's resistance is not irrational: after years of managing a complex condition through flares, hospitalizations, medication changes, and setbacks, achieving stability feels fragile, and the family fears that a new team will not understand the history or replicate the stability. The nurse must acknowledge this before explaining. The core explanation has two parts. First, pediatric subspecialty training programs — pediatric rheumatology, pediatric pulmonology, pediatric cardiology, pediatric gastroenterology — are designed for patients from birth to 18 to 21 years of age. The pediatric cardiologist's training, monitoring protocols, and reference ranges are calibrated for the pediatric patient. The pediatric rheumatologist follows JIA-specific JADAS-71 criteria. When a patient crosses 18, the pediatric specialists begin referring to adult subspecialties not because they want to end the relationship but because adult subspecialty medicine has different protocols, different monitoring parameters, and different knowledge bases for the adult manifestations of childhood-onset disease. An adult RA specialist monitors cardiovascular risk, bone density, and work disability in ways a pediatric rheumatologist does not, because these are the outcomes that matter in the adult disease trajectory. Second, the transfer is coordinated, not a handoff to an unknown team. The pediatric center produces a comprehensive transfer packet — complete disease history, current medications and doses, vaccination record, imaging studies with measurements, educational accommodations, genetic and laboratory results, and the treating physician's cover letter describing the patient's clinical story. The receiving adult specialist reviews this packet before the first appointment. In the Spanish frame: 'La transferencia no es porque ustedes hayan hecho algo mal ni porque nosotros no queramos a Lucía. Es porque la formación de la medicina pediátrica llega hasta los 18 años. A partir de los 18, hay especialidades de adultos que tienen protocolos específicos para enfermedades que empezaron en la infancia — y esos protocolos incluyen cosas que en pediatría no hacemos todavía porque no aplican hasta que el paciente es adulto. El equipo del Dr. Rivera ya tiene el expediente completo de Lucía. No empiezan de cero.'

How do pediatric transition-to-adult-care clinic nurses explain to Spanish-speaking families why airway-clearance therapies must continue after Trikafta when FEV1 has normalized?

The Trikafta-fixed-everything conversation requires the nurse to distinguish between what the CFTR modulator does and what it does not do, because the dramatic improvement in lung function from elexacaftor/tezacaftor/ivacaftor is real and the family's conclusion that the disease is now resolved is a reasonable inference from the numbers — but it is incorrect. CFTR modulators correct the underlying protein defect: elexacaftor acts as a corrector, helping the misfolded F508del CFTR protein fold more correctly and traffic to the cell surface; tezacaftor acts as a second corrector; ivacaftor acts as a potentiator, increasing the probability that the correctly folded CFTR channel at the cell surface opens when stimulated. The result is dramatically improved CFTR function — ion channel conductance is restored enough to significantly increase airway surface liquid (ASL) hydration. More hydrated ASL moves more easily — mucociliary clearance velocity increases, and the cilia can sweep the thinner mucus up the airway. This explains the FEV1 improvement: less mucus obstruction, less air trapping, less chronic inflammation. But CFTR function in F508del homozygous patients on triple therapy reaches approximately 50 percent of normal channel function, not 100 percent. The ASL is better hydrated than before, but not as hydrated as a healthy person's. Mucus in CF airways still has abnormal rheologic properties. Neutrophil extracellular traps (NETs) — filamentous webs of DNA and protein released by neutrophils fighting chronic bacterial colonization — accumulate in CF airways and significantly increase mucus viscosity. Dornase alfa (recombinant human DNase I) cleaves the extracellular DNA backbone of NETs, reducing mucus viscosity through a completely different mechanism from CFTR correction. Hypertonic saline draws water osmotically into the airway surface, independently hydrating the mucus layer. Both of these therapies work through mechanisms that remain effective and additive alongside CFTR correction. The CF Foundation and adult CF center guidelines explicitly recommend continuing airway clearance therapies in patients on CFTR modulators. Studies of patients who discontinued airway clearance after Trikafta initiation showed FEV1 plateau at a lower level and higher rates of pulmonary exacerbation compared to patients who continued. The Spanish frame: 'El Trikafta funciona corrigiendo la proteína CFTR — hace que la proteína se doble mejor y abra el canal de cloro. Eso mejora la hidratación del moco en las vías respiratorias de Marco y es exactamente por qué el FEV1 subió de 62 a 84. Pero hay dos cosas que el Trikafta no elimina: primero, el Trikafta lleva la función del canal al 50 por ciento, no al 100 — el moco sigue siendo más espeso de lo normal. Segundo, las células del sistema inmune de Marco producen redes de ADN en los pulmones que hacen el moco todavía más espeso. El dornase alfa corta ese ADN — ese es un mecanismo diferente al Trikafta, y juntos hacen más de lo que cualquiera hace solo. La solución salina hipertónica jala agua hacia las vías respiratorias — otro mecanismo diferente. Cuando paramos esos dos, estamos dejando caer defensas que el Trikafta no puede reemplazar.'

How do pediatric transition-to-adult-care clinic nurses explain to Spanish-speaking families why a repaired congenital heart requires lifelong ACHD surveillance?

The my-child's-heart-was-fixed-in-surgery conversation requires the nurse to reframe what 'repaired' means in congenital heart disease, because for most families the word repair carries the same meaning as a broken bone that heals or an appendix that is removed: a problem that existed, was fixed, and is now gone. In congenital heart disease, repair is better understood as managed — the anatomy that was incompatible with survival or normal function has been corrected enough to allow growth and relatively normal activity, but the repaired heart retains structural and hemodynamic sequelae of both the original defect and the repair technique itself. In tetralogy of Fallot specifically, the standard repair — patch reconstruction of the right ventricular outflow tract (RVOT) and transannular patch pulmonary valvuloplasty — eliminates the original obstruction but inevitably creates pulmonary valve insufficiency: the patch produces a competent RVOT but leaves the pulmonary valve unable to close completely, allowing regurgitation of blood back from the pulmonary artery into the right ventricle with every heartbeat. This chronic volume overload causes the right ventricle to dilate gradually — often over 10 to 20 years — until the right ventricular volume reaches the point where function is compromised and surgical pulmonary valve replacement becomes necessary. The critical insight for families is that this process is completely silent: the patient feels nothing, can be active, competitive, an athlete — right up to the point where the RV dilation becomes large enough to compromise output. Symptoms emerge late, after the window for optimal surgical intervention has sometimes already closed. The entire purpose of annual ACHD surveillance is to follow the RV end-diastolic volume index on cardiac MRI — the most precise measurement of RV dilation — and identify the patient at RVEDI 160 to 170 ml/m² (the current surgical guideline threshold) rather than waiting for symptoms to force emergency surgery when RVEDI is 200+ ml/m² and RV recovery post-intervention is uncertain. Sofía's RVEDI 158 ml/m² means she is within 2 to 10 ml/m² of the threshold — the ACHD team is planning her next surgery now, as an elective procedure, which is the best possible position for her to be in. The Spanish frame: 'La cirugía a los 4 años corrigió el defecto que hacía que la sangre de Sofía no circulara bien. Pero la forma en que se hace esa cirugía deja la válvula pulmonar — la que separa el corazón derecho de los pulmones — incapaz de cerrar completamente. Eso significa que un poco de sangre regresa al corazón derecho en cada latido. A lo largo de 15 años, eso hizo que el ventrículo derecho de Sofía se fuera agrandando poco a poco. Sofía no siente nada — corre, entrena, compite. Pero en la imagen del corazón, el ventrículo derecho está en 158. La guía dice que cuando llega a 160 es el momento ideal para poner una nueva válvula. Si esperamos a que Sofía tenga síntomas, el ventrículo ya tiene demasiado daño. El trabajo de esta clínica es planear la cirugía que Sofía va a necesitar ahora, como cirugía programada, no de urgencia.'

How do pediatric transition-to-adult-care clinic nurses explain why the adult specialist changed the monitoring protocol or medication schedule after the transfer?

The adult-doctor-changed-everything conversation arises frequently in the first year after transition and is a source of significant anxiety for families who interpret any change from the pediatric protocol as a mistake, a downgrade, or evidence that the new team does not understand the patient's history. The nurse must acknowledge that the change is noticeable and the question is valid, then explain that differences between pediatric and adult protocols reflect different disease trajectories and monitoring needs, not different standards of care. Several concrete examples: In juvenile idiopathic arthritis transitioning to adult rheumatoid arthritis management, the JADAS-71 composite disease activity score used in pediatric rheumatology is replaced by DAS-28 or CDAI — the adult scoring systems. These instruments measure the same underlying construct (inflammation burden) using slightly different inputs and cutoffs calibrated for adult joint anatomy and disease patterns. The transition from JADAS to CDAI is not a step down in rigor — it is a step into the scoring system validated for the adult disease phase the patient has now entered. In cystic fibrosis, the adult CF center adds monitoring that the pediatric center may have performed less intensively: annual OGTT for CF-related diabetes screening, bone density DEXA every two years, colonoscopy at 40 years in CF patients given their elevated colon cancer risk, and assessment of work disability and insurance coverage. These additions are not corrections to the pediatric care — they are monitoring dimensions that become relevant in adulthood and are added on schedule. In adult congenital heart disease, the transition from pediatric cardiology to ACHD adds monitoring calibrated for the adult manifestations of specific repairs: arrhythmia surveillance, QRS duration monitoring as a marker of RV strain, functional capacity testing, and planning for future interventions that are scheduled in advance rather than as urgent procedures. The Spanish frame: 'Que la Dra. Rivera use diferentes escalas para medir la actividad de la enfermedad de Lucía no quiere decir que el equipo anterior lo hacía mal ni que ella no entiende el caso. En pediatría usamos JADAS-71 porque está validado para la enfermedad de Lucía de niña. En adultos se usa CDAI porque está validado para los pacientes adultos con la misma enfermedad. Es como medir la temperatura con Celsius en un laboratorio y con Fahrenheit en el hospital — el resultado mide lo mismo con diferente escala.'

What are the key Spanish phrases pediatric transition-to-adult-care clinic nurses use when explaining the transfer rationale, residual disease activity, and lifelong monitoring to Spanish-speaking families?

Pediatric transition-to-adult-care clinic nurses working with Spanish-speaking families need clinical Spanish for five recurring communication moments at the transfer: explaining why the transfer happens even when things are going well; explaining that the transfer is coordinated not an abandonment; explaining that repair or remission does not mean the underlying condition is gone; explaining why monitoring continues for asymptomatic patients; and explaining differences between pediatric and adult protocols. For the transfer rationale: 'La transferencia ocurre porque la medicina pediátrica está diseñada para pacientes de 0 a 18 años. A partir de los 18, existen especialidades de adultos con protocolos específicos para la fase adulta de su enfermedad — y eso le da a Lucía más, no menos. El equipo de adultos monitorea cosas que en pediatría todavía no necesitábamos monitorear.' For coordinated transfer: 'El equipo de la Dra. Rivera ya recibió el expediente completo de Lucía: toda su historia, sus medicamentos, sus vacunas, los resultados de su DEXA, el historial de sus articulaciones, la carta del Dr. García explicando el caso. No empiezan de cero — empiezan sabiendo todo.' For remission does not mean the disease is gone: 'Que Lucía esté en remisión no quiere decir que la enfermedad desapareció. Quiere decir que el tratamiento está funcionando y controlando la inflamación. Si paramos el tratamiento, la inflamación vuelve — porque la artritis juvenil es una condición autoinmune que no se cura, solo se controla.' For CFTR modulators and airway clearance: 'El Trikafta mejoró la función del canal CFTR — ese es un mecanismo. La solución salina hipertónica hidrata el moco con otro mecanismo. El dornase alfa corta el ADN del moco con un tercer mecanismo. Los tres actúan juntos y ninguno reemplaza a los otros.' For cardiac surveillance in repaired CHD: 'Que el corazón de Sofía esté reparado no quiere decir que ya no necesita vigilancia. La reparación crea su propio efecto a largo plazo — la válvula que no puede cerrar del todo. El trabajo de la clínica ACHD es planear la próxima intervención de Sofía antes de que los síntomas aparezcan, porque los síntomas llegan tarde.'

Spanish for pediatric transition-to-adult-care clinic nurses — the mother who cannot understand why her daughter with JIA is being transferred to adult rheumatology when she is finally in remission not knowing pediatric rheumatology training scope ends at 18 and the transfer is coordinated; the father who stopped airway-clearance therapies for cystic fibrosis after transfer believing Trikafta fixed everything not knowing CFTR modulators improve but do not normalize airway surface liquid and hypertonic saline and dornase alfa are additive; and the mother who cannot understand why a heart repaired at age 4 still requires annual ACHD cardiology surveillance not knowing tetralogy of Fallot repair leaves residual pulmonary regurgitation that silently enlarges the right ventricle until intervention timing becomes critical

The pediatric transition-to-adult-care clinic nurse’s communication challenge

The pediatric transition-to-adult-care clinic nurse works at a threshold defined by an institutional boundary and a biological one that do not coincide: pediatric subspecialty training and clinic scope end at 18 to 21 years, while the chronic conditions managed in those clinics — autoimmune arthritis, cystic fibrosis, congenital heart disease, metabolic disorders, oncologic late effects — continue for a lifetime. The family arrives at the transition clinic after years or decades of relationship with a pediatric team that knows their child’s complete history, has navigated every crisis with them, and has finally achieved whatever stability is achievable. The message they receive is that this relationship is ending. The nurse must explain that the ending is not an abandonment but a handoff, that the new team already has the history, and that adult subspecialty medicine offers monitoring dimensions that pediatric protocols do not yet include.

The communication challenge at transition is not primarily about the new clinic or the new doctor. It is about what the family believes the word “transfer” means, what they believe “remission” or “repaired” or “improved” means about the underlying condition, and what they understand about why a patient who feels completely well still requires surveillance and continuous treatment. Three misalignments recur with particular force in transition-to-adult-care clinics serving Spanish-speaking families.

The first is the transfer-when-things-are-good paradox. A 17-year-old girl has managed polyarticular JIA for 8 years. She has been on biologics, through flares, through medication changes, through school absences and accommodations. In the last 14 months she has been in inactive disease on the current regimen. The family finally feels secure. Then the transition appointment arrives and the message is: we are transferring you. The mother cannot understand why the team that knows her daughter, that achieved this stability, is leaving. The nurse must explain that pediatric subspecialty training scope ends, that the transfer is coordinated with a complete record handoff, and that the receiving adult rheumatologist will add monitoring for the cardiovascular and bone health consequences of long-standing systemic inflammation that the pediatric protocol does not yet require.

The second is the treatment-is-working-so-we-can-stop misalignment applied to a treatment that does not render other treatments redundant. An 18-year-old with cystic fibrosis has had a transformative response to elexacaftor/tezacaftor/ivacaftor. His FEV1 is 84 percent predicted. He looks and feels better than his family has seen in years. In the transition to the adult CF center, his father — seeing numbers that look close to normal — stops the hypertonic saline and dornase alfa, reasoning that the modulator has addressed the disease. The nurse at the adult CF center must explain that CFTR modulators correct the protein defect and dramatically improve function but do not normalize airway surface liquid, that mucus rheology in CF remains abnormal, that dornase alfa and hypertonic saline act through entirely different mechanisms that remain additive alongside CFTR correction, and that adult CF centers have data showing that stopping airway clearance after Trikafta initiation leads to earlier FEV1 plateau and more pulmonary exacerbations.

The third is the surgery-fixed-it misunderstanding about the natural history of surgical repair in congenital heart disease. A 19-year-old woman had her tetralogy of Fallot repaired surgically when she was 4 years old. She is asymptomatic, active, a competitive athlete. Her mother cannot understand why she needs an annual cardiology appointment for a heart that was fixed 15 years ago. The ACHD nurse must explain that tetralogy repair leaves pulmonary valve insufficiency that slowly enlarges the right ventricle over decades without producing symptoms until the window for optimal surgical intervention has sometimes already closed, that annual ACHD surveillance exists to catch the right ventricle at RVEDI 160 ml/m² — the guideline threshold for elective pulmonary valve replacement — rather than at emergency presentation, and that this patient’s RVEDI of 158 ml/m² means that second surgery is being planned now, as an elective procedure, which is exactly the right position to be in.

Three conversations from the pediatric transition-to-adult-care clinic:

Scenario 1: Lucía Morales-García — 17 years old, Houston, Texas

Lucía Morales-García had been diagnosed with polyarticular RF-positive juvenile idiopathic arthritis at age 9, three weeks after her third-grade teacher sent a note home saying Lucía had been having difficulty opening her juice bottle at lunch and asked whether she was feeling well. The morning stiffness had been present for months — her mother Verónica had attributed it to sleeping wrong, to the cold floor, to growing pains. The rheumatologist at Texas Children’s had seen inflamed MCP and PIP joints in both hands, elevated CRP at 3.4 mg/L, positive rheumatoid factor at 1:640, and positive anti-CCP antibody. The diagnosis had been unambiguous. RF-positive polyarticular JIA carries the highest risk of erosive joint disease among all JIA subtypes and follows a course more similar to adult seropositive rheumatoid arthritis than to the seronegative JIA variants.

The first two years had been difficult: methotrexate titrated to 15 mg per week oral, adequate for some months and not others, hydroxychloroquine added, a course of intra-articular triamcinolone in the right knee at the worst flare. At age 12, the decision had been made to start etanercept 50 mg subcutaneous weekly. The response had been good but not immediate: six months before flares were fully suppressed, then a three-month period of stability, then a relapse when Lucía had a respiratory infection at age 14 that had required a burst of oral prednisone. From age 14 to 15, the regimen had been adjusted — methotrexate dose, etanercept timing, addition of folic acid daily to reduce methotrexate side effects. By age 16, the combination was working consistently. At the last visit, 14 months earlier, the JADAS-71 had been 1.2 — inactive disease. At today’s visit, it was 0.8.

Lucía was sitting in the chair composing a text message, completely comfortable, relaxed in the way of a teenager who no longer thinks of herself as a patient between appointments. She had gotten her driver’s permit three months ago. She had a part-time job at a coffee shop. Her school attendance this year was 97 percent. Her mother Verónica was sitting beside her with her hands folded, and she had been quiet since they sat down.

The transition coordinator, nurse Rosa Espinoza-Fuentes, finished reviewing the chart and looked at them both. “El JADAS de hoy es 0.8 — eso es lo que queremos ver. Lucía, está haciendo exactamente lo que esperábamos.” (Today’s JADAS is 0.8 — that is what we want to see. Lucía, she is doing exactly what we hoped.)

Verónica unfolded her hands. “Entonces, ¿por qué la transfieren?” (So, why are you transferring her?)

Rosa had expected this. “Es la pregunta correcta, y voy a responderla bien.” (It is the right question, and I am going to answer it properly.)

“Durante ocho años, Lucía ha sido paciente de reumatología pediátrica. Ese equipo — el Dr. García, yo, todo el equipo — nos entrenamos en enfermedades reumáticas de 0 a 18 años. Nuestros protocolos, nuestras escalas de medición, los valores de referencia que usamos, el tipo de monitoreo que hacemos — todo está diseñado para pacientes pediátricos. Cuando un paciente como Lucía cumple 18, la enfermedad no cambia — pero la fase adulta de esa enfermedad requiere un tipo de monitoreo diferente, y existen especialistas adultos que se entrenaron específicamente para eso.” (For eight years, Lucía has been a patient of pediatric rheumatology. That team — Dr. García, me, all of us — we trained in rheumatic diseases from 0 to 18 years old. Our protocols, our measurement scales, the reference values we use, the type of monitoring we do — all of it is designed for pediatric patients. When a patient like Lucía turns 18, the disease does not change — but the adult phase of that disease requires a different type of monitoring, and there are adult specialists who trained specifically for that.)

Verónica looked at her daughter. “¿Qué quiere decir diferente?” (What do you mean by different?)

“Una de las cosas que la artritis reumatoide en adultos — que es lo que tiene Lucía ahora que tiene 17, la versión adulta de la misma enfermedad — requiere monitorear es el riesgo cardiovascular. La inflamación crónica que produce la AR acelera el endurecimiento de las arterias más rápido de lo normal. En la medicine pediátrica no lo monitoreamos aún porque el riesgo todavía está siendo acumulado, no expresado. Pero a los 18, los reumatólogos de adultos empiezan a monitorear presión arterial, perfil lipídico, y riesgo cardiovascular como parte del protocolo de la AR. Lucía va a tener más, no menos, cuando esté con el equipo adulto.” (One of the things that rheumatoid arthritis in adults — which is what Lucía has now at 17, the adult version of the same disease — requires monitoring is cardiovascular risk. The chronic inflammation produced by RA accelerates arterial hardening faster than normal. In pediatric medicine we do not yet monitor it because the risk is still accumulating, not expressed. But at 18, adult rheumatologists begin monitoring blood pressure, lipid profile, and cardiovascular risk as part of the RA protocol. Lucía will have more, not less, when she is with the adult team.)

Lucía had put down her phone. “¿Y el Dr. García le manda a la Dra. Rivera todo mi histórial?” (And does Dr. García send Dr. Rivera my entire history?)

“Ya lo hizo. La Dra. Rivera tiene un paquete con ocho años de historia clínica de Lucía: cada cambio de medicamento, cada brote, cada resultado de laboratorio, la historia de las articulaciones, el registro de vacunas — incluyendo la nota sobre que Lucía no puede recibir vacunas de virus vivos mientras está en etanercept — la carta del Dr. García explicando el caso, y la nota sobre los acomodos escolares. La Dra. Rivera va a leer todo eso antes de ver a Lucía por primera vez. No empieza desde cero.” (She already has. Dr. Rivera has a packet with eight years of Lucía’s clinical history: every medication change, every flare, every laboratory result, the joint history, the vaccination record — including the note that Lucía cannot receive live-virus vaccines while on etanercept — Dr. García’s letter explaining the case, and the note about school accommodations. Dr. Rivera is going to read all of that before seeing Lucía for the first time. She does not start from zero.)

Verónica was quiet for a moment. “¿Y si con la Dra. Rivera hay un brote? ¿Podemos llamar al Dr. García?” (And if there is a flare with Dr. Rivera? Can we call Dr. García?)

“El Dr. García va a estar disponible por correo electrónico durante el primer año de transición si surge alguna pregunta sobre la historia de Lucía. Pero lo que esperamos — y lo que la mayoría de los pacientes que hacen la transición con Lucía’s tipo de enfermedad bien controlada experientan — es que la Dra. Rivera conoce estas situaciones exactamente. Trabaja con pacientes adultos que llegaron como Lucía todos los años.” (Dr. García will be available by email during the first year of transition if any question arises about Lucía’s history. But what we expect — and what most patients who transition with Lucía’s type of well-controlled disease experience — is that Dr. Rivera knows these situations exactly. She works with adult patients who arrived like Lucía every year.)

Lucía looked at her mother. “Mamá, está bien. Ya tengo 17. No puedo quedarme en pediatría para siempre.” (Mom, it’s okay. I’m already 17. I cannot stay in pediatrics forever.)

Verónica looked at the nurse. “¿Y si Lucía sigue bien con la Dra. Rivera, sigue exactamente igual?” (And if Lucía continues to do well with Dr. Rivera, does she continue exactly the same?)

“El metotrexato y el etanercept continuarán. La escala de medición va a cambiar — la Dra. Rivera usa CDAI en lugar del JADAS-71 que usamos nosotros, porque CDAI es la escala validada para adultos. Los números son diferentes pero miden lo mismo. Lo que la Dra. Rivera va a añadir es el monitoreo cardiovascular: presión arterial, perfil lipídico, densidad ósea en el DEXA. Lucía va a tener más vigilancia, no menos.” (Methotrexate and etanercept will continue. The measurement scale will change — Dr. Rivera uses CDAI instead of the JADAS-71 we use, because CDAI is the validated scale for adults. The numbers are different but they measure the same thing. What Dr. Rivera will add is cardiovascular monitoring: blood pressure, lipid profile, bone density on DEXA. Lucía will have more surveillance, not less.)

Verónica exhaled. “Y la Dra. Rivera ya tiene el expediente.” (And Dr. Rivera already has the chart.)

“Desde la semana pasada.” (Since last week.)

Verónica nodded slowly. “De acuerdo,” she said. “Pero si algo pasa antes de la primera cita con ella, llamo aquí.” (All right. But if anything happens before the first appointment with her, I am calling here.)

“Por supuesto. Para eso estamos.” (Of course. That is what we are here for.)

Scenario 2: Marco Torres-Espinoza — 18 years old, San Antonio, Texas

Marco Torres-Espinoza had been born with cystic fibrosis diagnosed on the newborn screen at 3 days old — sweat chloride 104 mmol/L, CFTR genotype F508del/F508del homozygous, the most common CF genotype in the United States, representing approximately 85 percent of all CF patients. His early years had been defined by the standard pre-modulator CF regimen: twice-daily dornase alfa nebulization, vest airway clearance therapy, hypertonic saline three percent twice daily, fat-soluble vitamin supplementation, pancreatic enzyme replacement at every meal and snack. By age 12 his ppFEV1 had declined to 74 percent predicted. By age 14 it was 68. By age 16, the first hospitalization for a pulmonary exacerbation had occurred — Pseudomonas aeruginosa in his sputum, requiring two weeks of intravenous tobramycin and piperacillin-tazobactam.

Elexacaftor/tezacaftor/ivacaftor had been approved and covered by his insurance when Marco was 16. The pediatric CF team had started it within four months of approval. The change in the first three months had been striking: sweat chloride fell from 104 to 38 mmol/L. By six months, ppFEV1 had risen from 62 to 78 percent predicted. At twelve months, 84 percent. His BMI — which had been 16.2 kg/m² at initiation, reflecting the fat malabsorption and energy expenditure of moderate CF lung disease — had normalized to 20.1 kg/m². No pulmonary exacerbations in twenty months on triple therapy. No hospitalizations.

The transition to the adult CF center at University Hospital San Antonio had been scheduled for Marco’s 18th birthday. The pediatric CF team had prepared the standard transfer packet. At the first adult CF clinic appointment, four weeks after the transfer, the adult CF nurse coordinator María Cisneros-López had reviewed Marco’s medication list with his father Eduardo Torres-Mendoza, who had driven him from Converse and sat beside him during the entire intake visit.

“Marco — estás tomando el Trikafta, ¿verdad?” María asked, scanning the medication reconciliation form. (Marco — you are taking the Trikafta, right?)

“Sí,” Marco said. “Pero mi papá pensó que—” (Yes. But my dad thought that—)

Eduardo held up his hand. “Lo dejé yo. Paré la solución salina y el Pulmozyme hace como tres semanas. Con el FEV1 a 84, pensé que la enfermedad ya estaba manejada y que esos tratamientos eran de cuando Marco estaba mal. El Trikafta ya lo está curando, ¿no? Los pulmones ya funcionan casi normal. ¿Para qué seguir con todos esos tratamientos de la nebuliodora si ya no los necesita?” (I stopped them. I stopped the hypertonic saline and the Pulmozyme about three weeks ago. With FEV1 at 84, I thought the disease was already managed and those treatments were from when Marco was sick. The Trikafta is already curing him, right? His lungs work almost normally now. Why continue with all those nebulizer treatments if he does not need them anymore?)

María put down her pen. This was not the first time she had heard this. “Señor Torres, entiendo completamente por qué hizo eso. El FEV1 de 84 es una transformación real — de 62 a 84 en dos años es un cambio que en otra época no hubiera sido posible. Usted ve a Marco bien y quiere simplificar. Tiene toda la lógica del mundo. Lo que voy a explicarle es por qué, a pesar de eso, los otros dos tratamientos siguen haciendo algo que el Trikafta no puede hacer.” (Mr. Torres, I understand completely why you did that. The FEV1 of 84 is a real transformation — from 62 to 84 in two years is a change that in another era would not have been possible. You see Marco doing well and you want to simplify. It makes complete logical sense. What I am going to explain is why, despite that, the other two treatments continue doing something that Trikafta cannot do.)

Eduardo crossed his arms, but he was listening.

“El Trikafta funciona corrigiendo la proteína CFTR. En la fibrosis quística F508del, la proteína CFTR está plegada incorrectamente y no llega bien a la superficie de las células del pulmón. El elexacaftor y tezacaftor son correctores — ayudan a que la proteína se pliegue mejor y viaje a la superficie. El ivacaftor es un potenciador — aumenta la probabilidad de que el canal abra cuando debe. Juntos, logran que el canal CFTR funcione de manera muchísimo mejor de lo que funcionaba antes. Eso aumenta la hidratación de la capa de moco en las vías respiratorias de Marco — el moco es más fluido, los cilios pueden moverlo mejor, y eso explica el FEV1 a 84.” (Trikafta works by correcting the CFTR protein. In F508del cystic fibrosis, the CFTR protein is incorrectly folded and does not properly reach the surface of the lung cells. Elexacaftor and tezacaftor are correctors — they help the protein fold better and travel to the surface. Ivacaftor is a potentiator — it increases the probability that the channel opens when it should. Together, they make the CFTR channel function much, much better than it was before. That increases the hydration of the mucus layer in Marco’s airways — the mucus is more fluid, the cilia can move it better, and that explains the FEV1 of 84.)

Eduardo nodded. “Por eso digo que ya está corregido.” (That is why I say it is already corrected.)

“Parcialmente corregido — eso es importante. El Trikafta lleva la función del canal CFTR a aproximadamente el 50 por ciento de lo normal — no al 100. Las vías respiratorias de Marco están mucho mejor hidratadas que antes, pero no están tan hidratadas como las de una persona sin FC. El moco de Marco todavía tiene propiedades diferentes — es más viscoso, más difícil de mover — en comparación con alguien sin la mutación. El FEV1 a 84 no quiere decir que los pulmones de Marco funcionan igual que los de un joven sin FC. Quiere decir que funcionan como si Marco tuviera una enfermedad leve, no severa. Eso es transformador. Pero no es lo mismo que curado.” (Partially corrected — that is important. Trikafta brings CFTR channel function to approximately 50 percent of normal — not 100. Marco’s airways are much better hydrated than before, but they are not as hydrated as a person without CF. Marco’s mucus still has different properties — it is more viscous, harder to move — compared to someone without the mutation. FEV1 at 84 does not mean Marco’s lungs work the same as a young person without CF. It means they work as if Marco had mild disease, not severe. That is transformative. But it is not the same as cured.)

Marco was listening carefully. “¿Y el moco que todavía está ahí — para eso son los otros tratamientos?” (And the mucus that is still there — that is what the other treatments are for?)

“Exactamente. Los neutrófilos — las células del sistema inmune que combaten las bacterias — cuando mueren en las vías respiratorias de Marco liberan redes de ADN. Esas redes se mezclan con el moco y lo hacen mucho más espeso y pegajoso. Eso se llama trampas extracelulares de neutrófilos. El dornase alfa — el Pulmozyme — es una DNasa recombinante: una enzima que corta ese ADN en pedazos pequeños, rompiendo esas redes. Eso reduce la viscosidad del moco por un mecanismo completamente diferente al Trikafta. El Trikafta no corta ADN. No puede hacer lo que hace el dornase alfa. Son complementarios — juntos hacen más que cualquiera de los dos solo.” (Exactly. The neutrophils — the immune cells that fight bacteria — when they die in Marco’s airways they release networks of DNA. Those networks mix with the mucus and make it much thicker and stickier. That is called neutrophil extracellular traps. Dornase alfa — Pulmozyme — is a recombinant DNase: an enzyme that cuts that DNA into small pieces, breaking those networks. That reduces mucus viscosity through a completely different mechanism from Trikafta. Trikafta does not cut DNA. It cannot do what dornase alfa does. They are complementary — together they do more than either one alone.)

Eduardo unfolded his arms slightly. “¿Y la sal hipertónica?” (And the hypertonic saline?)

“La solución salina hipertónica jala agua hacia las vías respiratorias por osmosis — hidratación directa del moco desde afuera. Eso es un tercer mecanismo diferente: no corrige la proteína como el Trikafta, no corta el ADN como el dornase alfa — simplemente añade agua directamente al moco. Los tres funcionan por caminos distintos y juntos producen una limpieza mucho mejor que cualquiera solo. Tenemos datos de pacientes con FC que son F508del homozigoto como Marco, que estaban en Trikafta y dejaron el dornase alfa y la salina: sus FEV1 se estabilizaron a un nivel más bajo, y tuvieron más exacerbaciones pulmonares que los pacientes que continuaron con todos los tratamientos.” (Hypertonic saline pulls water into the airways by osmosis — direct hydration of the mucus from outside. That is a third different mechanism: it does not correct the protein like Trikafta, it does not cut DNA like dornase alfa — it simply adds water directly to the mucus. All three work through different pathways and together produce much better clearance than any one alone. We have data from CF patients who are F508del homozygous like Marco, who were on Trikafta and stopped the dornase alfa and saline: their FEV1s stabilized at a lower level, and they had more pulmonary exacerbations than patients who continued all treatments.)

Eduardo was very still. “¿Más exacerbaciones? ¿Como la hospitalización que tuvo Marco hace dos años?” (More exacerbations? Like the hospitalization Marco had two years ago?)

“Como esa, sí. Marco lleva 20 meses sin hospitalización con todos los tratamientos juntos. No queremos romper eso.” (Like that one, yes. Marco has gone 20 months without hospitalization with all treatments together. We do not want to break that.)

Marco looked at his father. “Papá, los tiempos en la nebuliodora no son tanto. Yo los hacía bien.” (Dad, the nebulizer times are not that long. I was doing them well.)

Eduardo looked at his son — the same kid who at 16 had been hospitalized with IV antibiotics, and who today looked unremarkably healthy. “¿Cuándo vuelven a hacerse los efectos?” (When do the effects return?)

“Lo más fácil es retomar esta semana y hacer la medición de FEV1 de nuevo en seis semanas. Queremos que Marco llegue a los 25, 35, 45 años con los pulmones en el mejor estado posible. El Trikafta es la base. Los otros son la defensa que el Trikafta no puede hacer solo.” (The easiest thing is to restart this week and take the FEV1 measurement again in six weeks. We want Marco to reach 25, 35, 45 years old with his lungs in the best possible state. Trikafta is the foundation. The others are the defense that Trikafta cannot do alone.)

“Esta semana,” Eduardo said. He looked at Marco. “Volvemos con todo.” (This week. We go back to all of them.)

“Gracias,” María said. “Marco — ¿tienes alguna pregunta?” (Thanks. Marco — do you have any questions?)

“Sí,” Marco said. “¿Hay una app para el vesá en el teléfono que me manda recordatorio? En el centro pediátrico la tenían.” (Yes. Is there an app for the vest on the phone that sends me a reminder? The pediatric center had one.)

“Sí. Te la descargamos hoy mismo.” (Yes. We will download it for you today.)

Scenario 3: Sofía Reyes-Cisneros — 19 years old, Dallas, Texas

Sofía Reyes-Cisneros had been born in Dallas with tetralogy of Fallot — the combination of ventricular septal defect, right ventricular outflow tract obstruction, right ventricular hypertrophy, and aortic override that is one of the most common cyanotic congenital heart defects, occurring in approximately 1 in 3,600 live births. She had been cyanotic at birth. The pediatric cardiologist at Children’s Medical Center Dallas had detected a murmur in the first hour of life, and the echocardiogram had confirmed the diagnosis. At 4 months she had required a modified Blalock-Taussig shunt as a palliative measure while she grew. At 4 years old she had undergone complete intracardiac repair: closure of the ventricular septal defect with a Dacron patch, resection of infundibular muscle bundles obstructing the RVOT, and placement of a transannular pericardial patch across the pulmonary valve annulus to relieve the outflow obstruction.

The repair had been technically successful. Sofía had grown up with normal activity restrictions. At 10 she had joined the track team. At 14 she had broken two school records in the 400 meters. At 19 she was on a partial athletic scholarship at University of North Texas. At her most recent cardiac MRI, performed three months earlier as part of her annual ACHD follow-up, the measurements had been: pulmonary regurgitation fraction 42 percent; right ventricular end-diastolic volume index 158 ml/m²; QRS duration 148 milliseconds. She felt nothing. She had felt nothing her entire life.

Her mother Carmela Reyes-Cisneros had come to Dallas from Monterrey when Sofía was diagnosed and had never left. She had been at every appointment for 19 years. But this year, for the first time, she had expressed something that had been building for a while.

“Mire,” she said to the ACHD nurse Rosa Hernández-Martínez, at the start of the follow-up visit. “Yo entiendo que tenemos que venir cada año. Pero yo no entiendo para qué. Sofía corre 400 metros. No tiene síntomas. La operaron cuando tenía 4 años. Eso fue hace 15 años. El corazón está reparado. ¿Por qué necesitamos seguir viniendo? No hay nada que arreglar.” (Look. I understand we have to come every year. But I do not understand why. Sofía runs 400 meters. She has no symptoms. They operated on her when she was 4 years old. That was 15 years ago. The heart is repaired. Why do we need to keep coming? There is nothing to fix.)

Rosa had heard versions of this question many times. The families who asked it were usually the ones who had done everything right for 15 years: every appointment kept, every medication given, every restriction respected. They were tired in the way of someone who had been vigilant for a very long time and could not see what they were still being vigilant for.

“Señora Reyes, la pregunta que usted hace es exactamente la pregunta que queremos que hagan, porque la respuesta explica todo lo que hace esta clínica. Le voy a explicar dos cosas: qué quedó después de la cirugía, y por qué lo que quedó hace que la vigilancia de Sofía sea ahora más importante que nunca.” (Mrs. Reyes, the question you ask is exactly the question we want you to ask, because the answer explains everything this clinic does. I am going to explain two things: what remained after the surgery, and why what remained makes Sofía’s surveillance now more important than ever.)

Carmela folded her hands. Sofía, in her university track sweatshirt, was looking at the cardiac MRI images on Rosa’s screen with the expression of someone who had seen these images many times.

“La cirugía a los 4 años corrigió el defecto que hacía que la sangre de Sofía no circulara bien: cerró el agujero entre los ventrículos, quitó el tejido muscular que bloqueaba la salida hacia los pulmones. Eso fue correcto y fue necesario y salvó la vida de Sofía y le permitió crecer y correr y hacer todo lo que hace. Pero la forma en que se hace esa reparación — el parche que se pone en la salida hacia los pulmones para abrir ese paso — deja la válvula pulmonar incapaz de cerrar completamente. Eso es inevitable con la técnica que se usa. La válvula pulmonar de Sofía tiene una fuga: en cada latido del corazón, cuando el ventrículo derecho bombea sangre hacia los pulmones, una parte de esa sangre regresa al ventrículo derecho.” (The surgery at age 4 corrected the defect that was preventing Sofía’s blood from circulating properly: it closed the hole between the ventricles, removed the muscle tissue blocking the exit toward the lungs. That was correct and necessary and saved Sofía’s life and allowed her to grow and run and do everything she does. But the way that repair is done — the patch placed at the exit toward the lungs to open that passage — leaves the pulmonary valve unable to close completely. That is unavoidable with the technique used. Sofía’s pulmonary valve has a leak: in each heartbeat, when the right ventricle pumps blood toward the lungs, a portion of that blood returns to the right ventricle.)

Carmela was very still. “¿Eso siempre estuvo ahí?” (Was that always there?)

“Desde los 4 años, sí. Sabemos que está ahí. Es parte de lo que el corazón de Sofía adaptó durante 15 años. La consecuencia de esa fuga — de que la sangre regrese al ventrículo derecho con cada latido — es que el ventrículo derecho tiene que trabajar más de lo normal. A lo largo de años, eso lo agranda. Lentamente, silenciosamente, sin que Sofía sienta nada. El corazón se adapta. Las células del músculo se estiran. El ventrículo se vuelve más grande.” (Since age 4, yes. We know it is there. It is part of what Sofía’s heart adapted to over 15 years. The consequence of that leak — of blood returning to the right ventricle with each heartbeat — is that the right ventricle has to work harder than normal. Over years, that enlarges it. Slowly, silently, without Sofía feeling anything. The heart adapts. The muscle cells stretch. The ventricle becomes larger.)

Rosa turned the screen slightly so Carmela could see the cardiac MRI measurements. “En la imagen de hace tres meses, el ventrículo derecho de Sofía mide 158 ml por metro cuadrado de superficie corporal. Las guías médicas para decidir cuándo cambiar la válvula pulmonar dicen que el momento óptimo es alrededor de 160 — cuando el ventrículo aún puede recuperarse completamente después de la cirugía, antes de que el estiramiento sea irreversible.” (In the image from three months ago, Sofía’s right ventricle measures 158 ml per square meter of body surface area. The medical guidelines for deciding when to replace the pulmonary valve say the optimal timing is around 160 — when the ventricle can still recover completely after surgery, before the stretching is irreversible.)

Carmela looked at the screen. “¿158 de 160?” (158 of 160?)

“De la zona donde queremos operar mientras es programada. No es un número de urgencia — Sofía está perfectamente estable ahora mismo. Pero sí nos dice que en el próximo año o dos vamos a planear la segunda cirugía. No esperar a que Sofía tenga síntomas, porque los síntomas en esto llegan tarde — cuando el ventrículo ya está demasiado estirado para recuperarse bien.” (Of the zone where we want to operate while it is elective. It is not an emergency number — Sofía is perfectly stable right now. But it does tell us that in the next year or two we are going to plan the second surgery. Not wait for Sofía to have symptoms, because symptoms in this condition arrive late — when the ventricle is already too stretched to recover well.)

Sofía turned from the screen. “¿Otra cirugía?” (Another surgery?)

“Sí. Pero una cirugía programada, planificada con tiempo, cuando el corazón de Sofía todavía puede recuperarse completamente. Eso es exactamente para lo que existe esta clínica — para asegurarnos de que cuando llegue ese momento, no sea una emergencia. Sea lo que siempre quisimos que fuera: una intervención que Sofía planea con meses de anticipación, con el equipo quírurgico que ella elija, en el momento oportuno.” (Yes. But a planned surgery, scheduled in advance, when Sofía’s heart can still recover completely. That is exactly why this clinic exists — to make sure that when that moment arrives, it is not an emergency. It is what we always wanted it to be: an intervention that Sofía plans months in advance, with the surgical team she chooses, at the right time.)

Carmela looked at her daughter. Sofía was looking at the cardiac MRI image on the screen — the enlarged right ventricle that had been adapting for 15 years without her knowing.

“¿Sigo corriendo mientras tanto?” Sofía asked. (Do I continue running in the meantime?)

“Mientras el ventrículo está donde está, actividad moderada-intensa es segura. No competencia de élite por ahora — vamos a revisar eso con el cardiolólogo en la visita de esta semana y ver si hay ajuste. Pero caminar, ejercicio moderado, vida activa — eso continuamos.” (While the ventricle is where it is, moderate-to-intense activity is safe. Not elite competition for now — we are going to review that with the cardiologist at this week’s visit and see if there is an adjustment. But walking, moderate exercise, active life — that continues.)

Carmela reached over and took her daughter’s hand. “¿Y viniendo cada año fue lo que nos puso en el momento correcto?” (And coming every year is what put us at the right moment?)

“Exactamente. Por eso venimos cada año.” (Exactly. That is why we come every year.)